Triazolopyridine inhibitors
Triazolopyridine inhibitors targeting SARM1 provide a therapeutic solution to inhibit axonal degeneration, addressing the lack of treatments for neurodegenerative diseases by modulating SARM1 activity and preventing neuronal signal disruption.
Patent Information
- Application Number
- PCT/US2026/028262
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
There are currently no approved medications for the treatment and/or prevention of axonal degeneration, which is an early event in neurodegenerative diseases such as peripheral neuropathy, traumatic brain injury, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, inherited neuropathy, and glaucoma, leading to neuronal signal disruption.
Development of triazolopyridine inhibitors targeting SARM1, an enzyme involved in axonal degeneration, to inhibit its activity and potentially slow or prevent the progression of these neurological conditions.
The triazolopyridine inhibitors effectively target SARM1, offering a therapeutic approach to treat or prevent axonal degeneration and associated neurological disorders by modulating SARM1 activity.
Smart Images

Figure US2026028262_19112026_PF_FP_ABST
Abstract
Description
Attorney Docket No. 059976-517001 WOTriazolopyridine InhibitorsBACKGROUND
[0001] Axonal degeneration is an important event in many neurodegenerative, neurological, and pathological disorders and conditions such as peripheral neuropathy, traumatic brain injury, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, inherited neuropathy, traumatic brain injury, and glaucoma. Damage or degeneration of axons leads to disruption of neuronal signal transmission.Evidence exists that axonal degeneration is an early event, preceding clinical symptoms in neurodegenerative diseases. Therefore, while neurological conditions have varying underlying etiologies, inhibition of axonal degeneration may slow or prevent the progression of the neurological conditions at their early stages.
[0002] These neurodegenerative, neurological, and pathological disorders and conditions affect millions of patients worldwide with costs exceeding several hundred billion dollars annually in the United States alone. There are currently no approved medications for the treatment and / or prevention of axonal degeneration.
[0003] Sterile Alpha and Toll / Interleukin receptor-1 (TIR) motif-containing 1 (SARM1) is an enzyme that is involved in axonal degeneration upon activation via axonal injury or forced dimerization of SARM1-TIR domains. SARM1 is enriched in neurons and promotes rapid breakdown of nicotinamide adenine dinucleotide (NAD+). Genetic knockout of SARM1 has been shown to be protective in several models of chemotherapy induced peripheral neuropathy. Thus, SARM1 is a potential therapeutic target to inhibit axonal degeneration and treat or prevent neurodegenerative, neurological, and pathological disorders and conditions.BRIEF SUMMARY
[0004] In one aspect, provided is a compound of Formula (I):Attorney Docket No. 059976-517001 WOor a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:X is N or CR’;R’ is hydrogen, halo, or C1-3 alkyl;L is absent or C1-2 alkylene;R1is C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl, or 3-10 membered heterocyclyl;R2is C6-12 aryl or 5-10 membered heteroaryl;R3is H, halo, -NR4R5, -CN, -OH, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C3-8 cycloalkyl; andR4and R5are each independently H or C1-3 alkyl,wherein each C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C6-12 aryl, 5-10 membered heteroaryl, C3- 8 cycloalkyl, and 3-10 membered heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, -OH, -NR6R7, C1-3 alkyl, and C1-3 alkoxy, wherein each C1-3 alkyl is optionally further substituted with - OH, and each R6and R7is independently H or C1-3 alkyl.
[0005] Also provided herein is a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
[0006] In another aspect, provided herein is a method of treating or preventing a disease associated with axonal degeneration in a patient, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
[0007] Also provided herein is a method of treating or preventing a disease associated with SARM1 activation in a patient, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
[0008] Also provided herein is a method of treating or preventing a disease selected from amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), diabetic neuropathy and chemotherapy-induced peripheral neuropathy in a patient, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Attorney Docket No. 059976-517001 WO
[0009] Other features and advantages of the present disclosure will be apparent from the following detailed description and figures, and from the claims.DETAILED DESCRIPTIONI. GENERAL
[0010] The present disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and / or hydrate, and / or cocrystal, and / or drug combination of the compound) that act as SARM1 modulators, e.g., SARM1 inhibitors. These chemical entities are useful, e.g., for treating a condition, disease or disorder in which aberrant SARM1 activity contributes to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., an inflammatory disease (e.g., atopic dermatitis)) in a subject (e.g., a human). The present disclosure also provides compositions containing the same, as well as methods of using and making the same.II. DEFINITIONSA. General Definitions
[0011] Before the present disclosure is further described, it is to be understood that this disclosure is not strictly limited to particular embodiments described, as such may of course vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the claims.
[0012] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present application is not entitled to antedate such publication by virtue of prior application. Further, the dates of publication provided may be different from the actual publication dates, which may need to beAttorney Docket No. 059976-517001 WOindependently confirmed. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in the publications that is herein incorporated by reference, the definition set forth in this section prevails over the definition incorporated herein by reference.
[0013] It is appreciated that certain features of the present disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the present disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations are also specifically embraced by the present disclosure and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.
[0014] When ranges of number values are disclosed, and the notation “from m... to nf’ is used, where n1 and n2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 pM (micromolar),” which is intended to include 1 pM, 3 pM, and everything in between to any number of significant figures (e.g., 1.255 pM, 2.1 pM, 2.9999 pM, etc.).
[0015] The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure, taking into account significant figures.
[0016] “A,” “an,” or “the” as used herein not only include aspects with one member, but also include aspects with more than one member. For instance, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of such cells and reference to “the agent” includes reference to one or more agents known to those skilled in the art, and so forth.Attorney Docket No. 059976-517001 WOB. Chemical Definitions
[0017] The term “alkyl” as used herein, alone or in combination, (sometimes abbreviated Aik) refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, the alkyl may comprise from 1 to 10 carbon atoms. In further embodiments, the alkyl may comprise from 1 to 6 carbon atoms, or from 1 to 4 carbon atoms. Alkyl can include any number of carbon, such as C1-2, C1-3, C1-4, C1-5, C1-6, C1-7, C1-8, C1-9, C1-10, C2-3, C2-4, C2-5, C2-6, C3-4, C3-5, C3-6, C4-5, C4-6 and C5-6. For example, C1-6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Alkyl can also refer to alkyl groups having up to 20 carbons atoms, such as, but not limited to heptyl, octyl, nonyl, decyl, etc. Alkyl groups can be substituted or unsubstituted. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (— CH2— ). Unless otherwise specified, the term “alkyl” may include “alkylene” groups. When the alkyl is methyl, it may be represented structurally as CH3, Me, or just a single bond terminating with no end group substitution.
[0018] The term “alkoxy” as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as defined herein. Alkoxy groups may have the general formula: alkyl-O-. As for alkyl group, alkoxy groups can have any suitable number of carbon atoms, such as C1-6. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 2-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, and the like. The alkoxy groups can be further optionally substituted as defined herein.
[0019] The term “halo” or “halogen” as used herein, alone or in combination, refers to fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo).
[0020] The term “haloalkyl” as used herein, alone or in combination, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogen atoms are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl, trihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl,Attorney Docket No. 059976-517001 WOdi chlorofluoromethyl, difluoroethyl, difluoropropyl, di chloroethyl and di chloropropyl.“Haloalkylene” refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (— CFH— ), difluoromethylene (— CF2— ), chloromethylene (— CHC1— ) and the like.
[0021] The term “hydroxy” as used herein, alone or in combination, refers to OH.
[0022] As used herein, the term “cycloalkyl” refers to a saturated or partially unsaturated mono- or bicyclic carbon group having 3 to 10 carbon atoms, such as C3-C10 cycloalkyl groups and C3-C6 cycloalkyl groups. Bicyclic cycloalkyl groups include fused, spiro, and bridged ring systems. Non-limiting examples of cycloalkyl groups include 2, 3 -dihydro- 1H-indene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[2.3]hexyl, spiro[3.3]heptanyl, and bicyclo[l.l.l]pentyl, bicyclo[2.2.1]heptyl, and spiro[2.5]octyl.
[0023] The term “heterocyclyl” refers to a saturated or partially unsaturated hydrocarbon monocyclic or bicyclic ring system, having 3 to 10 ring atoms, that is not aromatic, having at least one heteroatom within the ring selected from the group consisting of N, O and S.Bicyclic heterocyclyl groups include fused, spiro, and bridged ring systems. The heterocyclyl group may be denoted as, for example, a “5 to 10-membered heterocyclyl group,” which is a ring system containing 5, 6, 7, 8, 9 or 10 atoms, at least one being a heteroatom. Heterocyclyl groups can, for example, have 1, 2, 3, or more, heteroatoms. In some embodiments, a heterocyclyl group has one or two independently selected heteroatoms. A heterocycle may further comprise one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo-systems and thio- systems such as lactams, lactones, cyclic imides, cyclic thioimides and cyclic carbamates. The heterocyclyl group may be bonded to the rest of the molecule through any carbon atom or through a heteroatom such as nitrogen. Exemplary heterocyclyl groups include, but are not limited to azepanyl, 1,3-di oxolane, 1,4-dioxolanyl, maleimidyl, succinimidyl, dioxopiperazinyl, hydantoinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinonyl, thiazolinyl, thiazolidinyl, morpholinyl, oxiranyl, piperidinyl N-oxide, piperidinyl, piperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 2-oxopyrrolidinyl, tetrahydropyranyl, quinuclidineyl, 4H-pyranyl, azetidinyl, oxetanyl, octahydrocyclopenta[c]pyrrole, 2-azaspiro[3.3]heptanyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 4-azaspiro[2.5]octanyl, 6-azaspiro[3.5]nonanyl, 2,6-diazaspiro[3.3]heptanyl, 7-Attorney Docket No. 059976-517001 WOazabicyclo[2.2.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.2]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-oxabicyclo[2.1.1]hexanyl, 3-azabicyclo[3.2.1]octanyl, hexahydro- IH-cy cl openta[c]pyrrolyl, 3-oxa-9-azabicyclo[3.3.1]nonanyl, and hexahydro- 1H-pyrrolizinyl.
[0024] The term “aryl” as used herein, alone or in combination, refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. Exemplary aryls are hydrocarbon ring system radical comprising hydrogen and 6 to 10 carbon atoms and at least one aromatic ring; hydrocarbon ring system radical comprising hydrogen and 9 to 12 carbon atoms and at least one aromatic ring; hydrocarbon ring system radical comprising hydrogen and 12 to 15 carbon atoms and at least one aromatic ring; or hydrocarbon ring system radical comprising hydrogen and 15 to 18 carbon atoms and at least one aromatic ring. For purposes of this disclosure, the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
[0025] As used herein, the term “heteroaryl” refers to a 5- to 10-membered cyclic group wherein at least one ring in the system is aromatic; and wherein one or more carbon atoms in at least one ring in the system is / are replaced with a heteroatom independently selected from N, O, and S. Heteroaryls may be a monocyclic, bicyclic, tricyclic or tetracyclic ring systems, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. The heteroatom may be a member of an aromatic or non-aromatic ring, provided at least one ring in the heteroaryl is aromatic. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodi oxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4 benzodi oxanyl, benzonaphthofuranyl, benzoxazolyl, benzodi oxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotri azolyl, benzo[4,6]imidazo[l,2 a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2 oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1Attorney Docket No. 059976-517001 WOoxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1 phenyl 1H pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinol inyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl).
[0026] The term “cyano” as used herein, alone or in combination, refers to — CN.
[0027] The term “oxo” as used herein, alone or in combination, refers to =0.
[0028] In embodiments of the disclosure, any one of the positions that is understood to have a hydrogen may also exist or be understood to be isotopically enriched. In the compounds of this disclosure, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Obtaining 100% deuteration at any relevant site of a compound in an amount of milligram or greater can be difficult. Therefore, it is understood that some percentage of hydrogen may still be present, even though a deuterium atom is specifically shown in a chemical structure. Thus, when a chemical structure contains a “D,” the compound represented by the structure is deuterium-enriched at the site represented by “D ” Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its natural abundance isotopic composition. Also unless otherwise stated, when a position is designated specifically as “D” or “deuterium,” the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., the term “D” or “deuterium” indicates at least 50.1% incorporation of deuterium). In embodiments, a benzene ring may be optionally exist as -CeDs, -CeDFU, -C6D2H3, -C6D3H2, and -C6D4H. In embodiments, a cyclohexyl group may optionally exist as -C6Dn.
[0029] Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group.
[0030] The term “optionally substituted” means the anteceding group or groups may be substituted or unsubstituted. Groups constituting optional substitution may themselves be optionally substituted. For example, where an alkyl group is embraced by an optionalAttorney Docket No. 059976-517001 WOsubstitution, that alkyl group itself may also be optionally substituted. When substituted, the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: alkyl, alkenyl, alkynyl, alkanoyl, heteroalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, lower perhaloalkyl, perhaloalkoxy, cycloalkyl, phenyl, aryl, aryloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl, carboxyl, alkylcarbonyl, carboxyester, carboxamido, cyano, hydrogen, halogen, hydroxy, amino, alkylamino, arylamino, amido, sulfonamido, thioamido, nitro, thiol, alkylthio, haloalkylthio, perhaloalkylthio, arylthio, sulfonate, sulfonic acid, tri substituted silyl, N3, SH, SCH3, C(O)CHs, CO2CH3, CO2H, pyridinyl, thiophene, furanyl, carbamate, thiocarbamate, thiourea, and urea. Particular subsets of optional substitution include, without limitation: (1) alkyl, halo, and alkoxy; (2) alkyl and halo; (3) alkyl and alkoxy; (4) alkyl, aryl, and heteroaryl; (5) halo and alkoxy; and (6) hydroxyl, alkyl, halo, alkoxy, and cyano. Where an optional substitution includes a heteroatom-hydrogen bond (-NH-, SH, OH), further optional substitution of the heteroatom hydrogen is contemplated and includes, without limitation, optional substitution with alkyl, acyl, alkoxymethyl, alkoxyethyl, arylsulfonyl, alkyl sulfonyl, arylsulfoximinyl, or alkylsulfoximinyl, any of which are further optionally substituted. These subsets of optional substitutions are intended to be merely exemplary and any combination of 2 to 5, or 2 to 10, or 2 to 20 of the groups recited above up to all the group recited above and any subrange in between are contemplated. “Optionally substituted” may include any of the chemical functional groups defined hereinabove and throughout this disclosure. Two optional substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring comprising zero to three heteroatoms, for example forming methylenedioxy or ethylenedi oxy. An optionally substituted group may be unsubstituted (e.g., — CH2CH3), fully substituted (e.g., — CF2CF3), monosubstituted (e.g., — CH2CH2F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., — CH2CF3).
[0031] The various optional substitutions need not be the same, and any combination of optional substituent groups may be combined. For example, a carbon chain may be substituted with an alkyl group, a halo group, and an alkoxy group. Where substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particularAttorney Docket No. 059976-517001 WOmoiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted with.”
[0032] Asymmetric centers, axial asymmetry (non-interchanging rotamers), or the like may exist in the compounds of the various embodiments disclosed herein. Such chirality may be designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom or the relevant axis. It should be understood that embodiments encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, d-isomers and 1-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds of the various embodiments disclosed herein may exist as geometric isomers. The various embodiments disclosed herein includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. Additionally, compounds may exist as tautomers, including keto-enol tautomers; all tautomeric isomers are embraced by the embodiments disclosed herein.
[0033] Additionally, the compounds of the various embodiments disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the various embodiments disclosed herein.
[0034] Compounds provided herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. That is, an atom, in particular when mentioned in relation to a compound according to the present disclosure, includes all isotopes and isotopic mixtures of that atom, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. For example, when hydrogen is mentioned, it is understood to refer to1H,2H,3H or mixtures thereof; when carbon is mentioned, it is understood to refer tonC,12C,13C,14C or mixtures thereof; when nitrogen is mentioned, it is understood to refer to13N,14N,15N or mixturesAttorney Docket No. 059976-517001 WOthereof; when oxygen is mentioned, it is understood to refer to14O,15O,16O,17O,18O or mixtures thereof; and when fluoro is mentioned, it is understood to refer to18F,19F or mixtures thereof; unless expressly noted otherwise. For example, in deuteroalkyl and deuteroalkoxy groups, where one or more hydrogen atoms are specifically replaced with deuterium (2H). As some of the aforementioned isotopes are radioactive, the compounds provided herein therefore also comprise compounds with one or more isotopes of one or more atoms, and mixtures thereof, including radioactive compounds, wherein one or more nonradioactive atoms has been replaced by one of its radioactive enriched isotopes. Radiolabeled compounds are useful as therapeutic agents, e.g., cancer therapeutic agents, research reagents, e.g., assay reagents, and diagnostic agents, e.g., in vivo imaging agents. All isotopic variations of the compounds provided herein, whether radioactive or not, are intended to be encompassed within the scope of the present disclosure.Salts and Prodrugs of Compounds
[0035] Any reference to a compound of Formula (I) in connection with the present disclosure should be understood to include the tautomers, racemates, enantiomers and diastereomers thereof, if any, the mixtures thereof as well as the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or metabolites, or prodrugs thereof.
[0036] The compounds disclosed herein can exist as pharmaceutically acceptable salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable.However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002). It is understood that each of the compounds disclosed herein, and each embodiment of the compounds set forth herein, include pharmaceutically acceptable salts of such compounds.
[0037] It will further be appreciated that the compounds of Formula (I) or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present disclosure. For example, compounds of Formula (I), and saltsAttorney Docket No. 059976-517001 WOthereof can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
[0038] In some embodiments, the compounds of Formula (I) include the compounds of Table 1 and stereoisomers, pharmaceutically acceptable salts, and solvates thereof. In some embodiments, the compounds of Table 1 are in the free base form. In some embodiments, the compounds of Table 1 are in the form of a pharmaceutically acceptable salt.
[0039] The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and pharmaceutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesityl enesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, paratoluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds of the various embodiments disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the various embodiments disclosed herein contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
[0040] The term “prodrug” refers to a compound that is made active in vivo through chemical reaction in vivo thereby releasing an active compound. Compounds disclosed hereinAttorney Docket No. 059976-517001 WOcan be modified to exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the active compound. Additionally, prodrugs can be converted to the active compounds by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the active compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug is a compound which is administered as an ester (the “prodrug”), which is then metabolically hydrolyzed to the carboxylic acid, as the active entity. Additional examples include peptidyl derivatives of a compound. The term “therapeutically acceptable prodrug” refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of subjects without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use.C. Treatment-related Definitions
[0041] The phrase “effective amount” means an amount of compound that, when administered to a subject in need of such treatment, is sufficient to (i) treat a cancer and / or an allergic or inflammatory disease or disorder, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein. The amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, and the identity (e.g., weight) of the subject in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
[0042] A “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay orAttorney Docket No. 059976-517001 WOminimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and / or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient for inhibition of a SARM1 protein or gene. In certain embodiments, a therapeutically effective amount is an amount sufficient for treating an allergic or inflammatory disease or other SARM1-dependent disorder.
[0043] “Disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein. In some embodiments, the disease is a cancer. In some embodiments, the disease is an allergic or inflammatory disease or disorder.III. COMPOUNDS
[0044] In one aspect, provided is a compound of Formula (I):or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:X is N or CR’;R’ is hydrogen, halo, or C1-3 alkyl;L is absent or C1-2 alkylene;R1is C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl, or 3-10 membered heterocyclyl;R2is C6-12 aryl or 5-10 membered heteroaryl;R3is H, halo, -NR4R5, -CN, -OH, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C3-8 cycloalkyl;andR4and R5are each independently H or C1-3 alkyl,Attorney Docket No. 059976-517001 WOwherein each Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkoxy, C6-12 aryl, 5-10 membered heteroaryl, C3- 8 cycloalkyl, and 3-10 membered heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, -OH, -NR6R7, C1-3 alkyl, and C1-3 alkoxy, wherein each C1-3 alkyl is optionally further substituted with - OH, and each R6and R7is independently H or C1-3 alkyl.
[0045] In some embodiments, X is N.
[0046] In some embodiments, L is absent. In some embodiments, L is C1-2 alkylene optionally substituted with C1-3 alkyl. In some embodiments, L is -CH2- or -CH(CH3)-.
[0047] In some embodiments, R1is 5-10 membered heteroaryl, C3-8 cycloalkyl, or 3-10 membered heterocyclyl, each of which is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, and C1-3 alkyl, wherein the C1-3 alkyl is optionally further substituted with -OH. In some embodiments, R1is oxadiazolyl, phenyl, or piperidinyl. In some embodiments, R1is C3-8 cycloalkyl. In some embodiments, R1is cyclopropyl, cyclobutyl, cyclopentyl, spiro[3.3]heptanyl, or spiro[3.4]octanyl.,
[0050] In some embodiments, R2is pyridyl, triazolyl, or pyrimidinyl, each of which is optionally substituted with one or more substituents selected from the group consisting of halo and C1-3 alkyl. In some embodiments, R2is pyridyl.
[0051] In some embodiments, R3is -NR4R5, C1-6 alkyl, or C1-6 haloalkyl. In some embodiments, R3is -NH2, -CH3, or CF3.
[0052] In some embodiments, the compound of Formula (I) is a compound of Table 1, or a pharmaceutically acceptable salt thereof.Attorney Docket No. 059976-517001 WOTable 1. CompoundsAttorney Docket No. 059976-517001 WOAttorney Docket No. 059976-517001 WOAttorney Docket No. 059976-517001 WOAttorney Docket No. 059976-517001 WOThe stereochemistry of the compounds of Table 1 is arbitrarily assigned unless stated otherwise.Attorney Docket No. 059976-517001 WO
[0053] In some embodiments, a compound of formula (I) is selected from the groupAttorney Docket No. 059976-517001 WOCompositionsA. Pharmaceutical Compositions
[0054] While it may be possible for the compounds disclosed herein to be administered as the raw chemical, it is also possible to present them as a pharmaceutical composition (i.e., as a formulation). Accordingly, provided herein are pharmaceutical compositions which comprise one or more of the compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers and optionally one or more other therapeutic ingredients. The carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences. The pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
[0055] In an aspect, provided herein is a pharmaceutical composition including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as the active ingredient can be prepared by intimately mixing the compound of Formula (I), or a1Attorney Docket No. 059976-517001 WOpharmaceutically acceptable salt thereof with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral).
[0056] The pharmaceutical compositions and methods of the present disclosure may be utilized to treat an individual in need thereof. In embodiments, the individual is a mammal such as a human, or a non-human mammal. When administered to an animal, such as a human, the composition or the compound is preferably administered as a pharmaceutical composition comprising, for example, a compound and a pharmaceutically acceptable carrier and / or excipient. Pharmaceutically acceptable carriers and excipients are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration (i.e., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution is pyrogen-free, or substantially pyrogen-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophiles for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition can also be present in a transdermal delivery system, e.g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as a lotion, cream, or ointment.
[0057] A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a compound. Such physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a self-emulsifying drug delivery system or a self microemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a compound. Liposomes, for example, which comprise phospholipids or otherAttorney Docket No. 059976-517001 WOlipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.
[0058] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0059] The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil, (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
[0060] A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin). The compound may also be formulated for inhalation. In embodiments, a compound may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same canAttorney Docket No. 059976-517001 WObe found in, for example, U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.
[0061] The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
[0062] Formulations of the compounds disclosed herein suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of a compound of the present disclosure as an active ingredient. Compositions or compounds may also be administered as a bolus, electuary or paste.
[0063] Solid dosage forms for oral administration (e.g., capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules and the like), may comprise the active ingredient mixed with one or more pharmaceutically acceptable earners, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as. for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solidAttorney Docket No. 059976-517001 WOpolyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) complexing agents, such as, modified and unmodified cyclodextrins; and (11) coloring agents. In the case of capsules (e.g., sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also include buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0064] Compressed tablets may be prepared using binders (for example, gelatin or hydroxypropylmethyl cellulose), lubricants, inert diluents, preservatives, disintegrants (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), and / or surface- active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[0065] The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules, pills and granules, may be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredients) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
[0066] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, oils (in particular, cottonseed, groundnut, com, germ,Attorney Docket No. 059976-517001 WOolive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[0067] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0068] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0069] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
[0070] The ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0071] Powders and sprays can contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0072] The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion. Pharmaceutical compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterileAttorney Docket No. 059976-517001 WOinjectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0073] Examples of suitable aqueous and non-aqueous carriers that may be employed in the pharmaceutical compositions include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0074] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
[0075] For use in the methods of this disclosure, active compounds can be administered per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
[0076] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
[0077] The selected dosage level will depend upon a variety of factors including the activity of the particular compound or combination of compounds employed, or the ester, salt or amide thereof) the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compound(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.Attorney Docket No. 059976-517001 WOB. Combination Therapies
[0078] In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt thereof) in combination with one or more additional therapeutic agents. In some embodiments, the additional therapeutic agent is an anti-cancer agent. In some embodiments, the additional therapeutic agent is an anti-inflammatory agent.
[0079] In any case, the multiple therapeutic agents (at least one of which is a compound of the various embodiments disclosed herein) may be administered in any order or simultaneously. If administered simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.
[0080] In certain embodiments, a compound of the present disclosure, or a composition thereof, may be administered in combination with another modulator, agonist or antagonist of SARM1. In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, may be administered in combination with one or more other therapeutic agents.IV. METHODS
[0081] In some aspects, the compounds and pharmaceutical compositions described herein are useful in a condition responsive to the modulation of SARM1. Thus, provided herein are methods of treating a condition responsive to the modulation (e.g., inhibition) of SARM1 in a subject, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof.
[0082] Also provided is the use of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a condition responsive to the modulation (e.g., inhibition) of SARM1. Also provided is a compound described herein, or a pharmaceutically acceptable salt thereof, or aAttorney Docket No. 059976-517001 WOpharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof, for use in treating a condition responsive to the modulation (e.g., inhibition) of SARM1.
[0083] In some aspects, the provided compounds bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1). In some embodiments, the provided compounds inhibit activity of SARM1. In some embodiments, the provided compounds alleviate one or more attributes of neurodegeneration.
[0084] In some embodiments, the compounds and pharmaceutical compositions described herein are useful in a method of treating a neurodegenerative disease or disorder associated with axonal degeneration. In some embodiments, the compounds and pharmaceutical compositions described herein are useful in a method of treating, preventing, or ameliorating of axonal degeneration. In some embodiments, the compounds and pharmaceutical compositions described herein are useful in the inhibition of axonal degeneration. In some embodiments, the compounds and pharmaceutical compositions described herein are useful in a method of preventing degeneration of an axon distal to an axonal injury. In some embodiments, the compounds and pharmaceutical compositions described herein are useful in a method of treating one or more neurodegenerative diseases, disorders, or conditions associated with axonal degeneration. In some embodiments, a neuropathy associated with axonal degeneration is a hereditary or congenital neuropathy or axonopathy. In some embodiments, a neuropathy associated with axonal degeneration results from a de novo or somatic mutation. In some embodiments, a neuropathy associated with axonal degeneration is selected from a list contained herein. In one aspect, provided is a method of increasing the level of NAD+ in a sample or in a patient, comprising contacting the sample or administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof, wherein the increased level of NAD+ is relative to the level of NAD+ prior to the contacting or administering.
[0085] In one aspect, provided herein is a method of treating or presenting a disease associated with axonal degeneration in a patient, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided is use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease associated with axonal degeneration. In another aspect, provided hereinAttorney Docket No. 059976-517001 WOis a method of treating or preventing a disease associated with SARM1 activation in a patient, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided is use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease associated with SARM1 activation. In another aspect, provided herein is a method of treating or preventing a disease selected from amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), diabetic neuropathy, and chemotherapy-induced peripheral neuropathy in a patient, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided is use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease selected from amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), diabetic neuropathy, and chemotherapy-induced peripheral neuropathy.
[0086] In one aspect, a condition responsive to the modulation (e.g., inhibition) of SARM1 or a condition associated with axonal degeneration includes, but is not limited to, Parkinson’s disease, Parkinsonian syndromes or Parkinson’s plus syndromes such as, for example, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and corticobasal degeneration, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), a demyelinating disease such as, for example, multiple sclerosis, ischemia or stroke, chemical injury, and thermal injury.
[0087] In some embodiments, the compounds described herein are useful in the prevention of neurodegenerative diseases. Examples of neurological disorders treatable or preventable according to the methods described herein include spinal muscular atrophy (SMA), Chemotherapy Induced Peripheral Neuropathy (representative chemotherapeutic agents include vinca-alkaloids, taxols and platins), multiple sclerosis (MS), traumatic brain injury (TBI), spinal cord injury, stroke, Parkinson’ disease, glaucoma, Huntington’s disease, Alzheimer’s disease, Charcot-Marie-Tooth disease (CMT), retinitis pigmentosa (RP), age-related macular degeneration (AMD), small fiber neuropathies, peripheral neuropathy (e.g., viral neuropathy), spinocerebellar ataxias, cystic fibrosis, familial amyloidotic polyneuropathy, spongiform encephalopathies, spinal and bulbar muscular atrophy, hereditary dentatorubral-pallidoluysian atrophy, adrenoleukodystrophy, adrenomyeloneuropathy, Alexander’s disease, amyotrophic lateral sclerosis (ALS), Bassen-Kornzweig syndrome, Bell’s palsy, progressive supra nuclear palsy (PSP), central pontineAttorney Docket No. 059976-517001 WOmyelolysis, cluster headache, congenital hypomyelination, corticobasal degeneration, Creutzfeldt- Jakob disease, epilepsy, dementia (e.g., frontotemporal dementia and Lewy body dementia), demyelination disorders (e.g., ischemic demyelination), encephalomyelitis, Friedrich’s ataxia, Gaucher’s disease, hereditary sensory and autonomic neuropathy (HSAN), Hurler syndrome, Krabbe’s disease, metachromatic leukodystrophy, migraine and tension headaches, mild cognitive impairment, motor spinoneuron disease, neuromyelitis optica, Niemann-Pick disease, optic neuritis, Pelizaeus Merzbacher disease, peripheral neuropathy, periventricular leukomalacia, post-herpetic neuralgia, prion disease, progressive supranuclear palsy, progressive multifocal leukoencephalopathy, Tay-Sacks disease, thoracic disc herniation, traverse myelitis, trigeminal neuralgia, Wallerian degeneration, cerebellar degeneration, chiari malformation, dystonia, encephalitis (e.g., pediatric viral encephalitis and La Crosse virus encephalitis), hyperekplexia, multifocal motor neuropathy, muscular dystrophy, myasthenia gravis, myopathy, neurofibromatosis, neuronal ceroid lipofuscinosis, neuropathies (e.g., peripheral neuropathy), pseudobulbar affect, restless legs syndrome, spina bifida, syringomyelia, thoracic outlet syndrome, and transverse myelitis.
[0088] In certain aspects, a pharmaceutical composition described herein is formulated for administration to a patient in need of such composition. Pharmaceutical compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the pharmaceutical compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
[0089] In some embodiments, the pharmaceutical compositions are administered orally.
[0090] A specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease beingAttorney Docket No. 059976-517001 WOtreated. The amount of a compound described herein in the composition will also depend upon the particular compound in the pharmaceutical composition.
[0091] In some embodiments, the compounds described herein can be used to inhibit activity or a function of SARM1 in a cell.V. EXAMPLES
[0092] The following examples are provided to further aid in understanding the disclosed embodiments and presuppose an understanding of conventional methods well known to those persons having ordinary skill in the art to which the examples pertain. The particular materials and conditions described hereunder are intended to exemplify particular aspects of embodiments disclosed herein and should not be construed to limit the reasonable scope thereof.
[0093] Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, e.g., Smith, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7thedition, Wiley-Interscience, 2013.)
[0094] Compounds as described herein can be purified by any of the means known in the art, including chromatographic means, such as high performance liquid chromatography (HPLC), preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. For example, disclosed compounds can be purified via silica gel chromatography. See, e.g., Introduction to Modern Liquid Chromatography, 3rded., ed. L. R. Snyder, J. J. Kirkland, J. W. Dolan. John Wiley and Sons, 2011; and Thin Layer Chromatography, E. Stahl (ed.), Springer- Verlag, New York, 1969.
[0095] All solvents and reagents were obtained from commercial sources and used without further purification unless indicated otherwise. Anhydrous solvents were purchased and used as supplied. Reactions were monitored by thin-layer chromatography (TLC), visualizing with a UV lamp (254 nm) and KMnO4 stain.
[0096] NMR spectra were obtained on a Bruker Neo 400M spectrometer operating at 400 MHz. Chemical shifts are reported in parts per million (6) from the tetramethylsilane resonance in the indicated solvent.Attorney Docket No. 059976-517001 WO
[0097] LC-Mass spectra were taken with Agilent 1260-6125B single quadrupole mass spectrometer using a Welch Biomate column (C18, 2.7 um, 4.6*50 mm) or waters H-Class SQD2 system using a Welch Ultimate column (XB-C18, 1.8 um, 2.1*50 mm) eluting with two kinds of mixed solvents [one is mixture of solvents A (water with 0.05% FA) and B (ACN with 0.05% FA, another one is mixture of solvents A (water with 10 mM NH4HCO3) and B (ACN)] using a gradient elusion. Detection was by DAD (254 nm and 210 nm and 280 nm). Ionization was by ESI. The spectra were analyzed using Chemstation software.
[0098] Analytical HPLC was performed on the Waters ARC system either under acid-containing condition on a YMC Pack Pro column (C18 S-3um, 12nm, 150*2.0mm) eluting with a mixture of solvents A (Water with 0.05% FA) and B (ACN with 0.05% FA) or under base-containing condition on a Agilent Poroshell HPH C18 column (2.7um, 2.1* 150mm) eluting with a mixture of solvents C (Water with 0.1% NH3H2O) and D (ACN with 0.1% NH3H2O) using a gradient elution. The detection was by DAD (254 nm and 210 nm and 280 nm).
[0099] Chiral HPLC was performed on the waters acquity UPC2 system under basecontaining on Daicel chiralpak AD-H (5 um, 4.6*250 mm), Daicel chiralpak OD-H (5 um, 4.6*250 mm), Daicel chiralpak IG-3 (3 um, 4.6*150 mm), Chiral Technologies Europe AD-3 (3 um, 3.0*150 mm) and Trefoil TM Technology Trefoil TM AMY1 (2.5 um, 3.0*150 mm) with mobile phase (CO2: MeOH(0.1% DEA)) using a gradient elution. The detection was by DAD (254 nm).
[0100] Preparative HPLC was performed on GILSON Trilution LC system using a Welch XB-C18 column (5um, 21.2*150 mm), eluting with two kinds of solvents [one is the mixture of solvents A (Water with 0.1%FA) and B(ACN), another one is the mixture of solvents A (water with 10 mM NH4HCO3) and B (ACN)].
[0101] Chiral separation was performed by supercritical fluid chromatography (SFC) on waters SFC 80Q using Daicel Chiralcel OD / OJ / OZ (20 x 250 mm, 10 um) and Daicel Chiralpak IC / IG / IH / AD / AS (20 x 250 mm, 10 um) eluting with a mixture of solvents A (CO2) and B (MeOH, EtOH or IP A, containing 0.1% DEA). The detection was by PDA (254 nm, 210 nm and 280 nm).
[0102] Flash chromatography was carried out on Biotage Isolera Prime system using Welch WelFlash flash columns (40-63 um) eluting with a mixture of solvents as indicated in the experimental procedures.Attorney Docket No. 059976-517001 WO
[0103] The compounds synthesized are all with purity > 95% unless otherwise specified.
[0104] The Examples provided herein describe the synthesis of compounds disclosed herein as well as intermediates used to prepare the compounds. It is to be understood that individual steps described herein may be combined. It is also to be understood that separate batches of a compound may be combined and then carried forth in the next synthetic step.
[0105] Representative syntheses of compounds of the present disclosure are described in schemes below, and the particular examples that follow.
[0106] Abbreviations. Certain abbreviations and acronyms are used in describing the experimental details. Although most of these would be understood by one skilled in the art, the following table contains a list of many of these abbreviations and acronyms.Table 2. List of abbreviations and acronyms.Attorney Docket No. 059976-517001 WOExample A-l & A-2: (l?)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyi'idin-3-amine and (5)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (note: absolute configuration was arbitrarily assigned for both the enantiomers)Attorney Docket No. 059976-517001 WOStep-A: 3-bromo-2-hydrazineyl-4-methylpyridine
[0107] To a stirred solution of 3-bromo-2-chloro-4-methyl-pyridine (5.00 g, 24.22 mmol) in 1,4-dioxane (50 mL) was added hydrazine hydrate (50 mL) and the reaction mixture was stirred at 110 °C for 16 h. It was then cooled to room temperature, the solid thus obtained was filtered, washed with water (5 mL x 2) and dried to afford 3-bromo-2-hydrazineyl-4-methylpyridine (4 g, 81% yield) as a yellow solid. LC-MS: m / z 202 [M+H]+ / 204.Step-B: 2-(3-bromo-4-methylpyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)hydrazine-l-carb oxami de
[0108] To a stirred solution of triphosgene (402 mg, 1.35 mmol) in anhydrous CH2CI2 (15 mL) was added spiro[3.3]heptan-3-amine (400 mg, 2.71 mmol, HC1 salt) and TEA (548 mg, 5.42 mmol) at 0 °C under N2 atmosphere. The reaction mixture was stirred at room temperature for 2 h before addition of a solution of 3-bromo-2-hydrazineyl-4-methylpyridine (821 mg, 4.06 mmol) and TEA (1.37 g, 13.55 mmol) in CH2CI2 (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 16 h, before volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-80% EtOAc in petroleum ether) to afford 2-(3-bromo-4-methylpyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)hydrazine-l-carboxamide (760 mg, 49% yield, 60% purity by LCMS) as a yellow solid. LC-MS: m / z 339 [M+H]+ / 341.Step-C: 8-bromo-7-methyl-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine
[0109] To a stirred solution of 2-(3-bromo-4-methylpyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)hydrazine-l -carboxamide (60% pure, 85 mg, 0.25 mmol) and pyridine (60 mg, 0.75 mmol) in toluene (5 mL) at 50 °C was added POCI3 (46 mg, 0.3 mmol) drop wise. The reaction mixture was stirred at 50 °C for 1.5 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature and poured into an aqueous saturated solution of NaHCCh (30 mL). Extraction was carried out using EtOAc (30 mL x 3), the combined organic extracts were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-50% EtOAc in petroleum ether) to afford 8-bromo-7-methyl-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine as a yellow solid (24 mg, 50% yield). LC-MS: m / z 321 [M+H]+ / 323.Attorney Docket No. 059976-517001 WOStep-D: 7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine
[0110] Argon gas was purged through a stirred solution of 8-bromo-7-methyl-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (40 mg, 0.13 mmol) and 2-(tributylstannyl)pyridine (92 mg, 0.25 mmol) in DMF (5 mL) for 5 min before addition of Pd(tBu3P)2(12.78 mg, 0.025 mmol). The reaction mixture was then stirred at 110 °C for 2 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature and volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-12% MeOH in CH2Q2) followed by preparative HPLC to afford 7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine (6.4 mg, 0.02 mmol, 15% yield) as a yellow solid. LCMS: m / z 320 [M+H]+.Step-E: (5)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyri din-3 -amine & (A)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine
[0111] A racemic mixture of 7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine (95 mg, 0.3 mmol) was resolved by chiral-HPLC {Column: CHIRALPAK IM, 2 x 25 cm, 5 pm; mobile phase A: hexane, mobile phase B: EtOH: CH2C12=1: 1; flow rate: 20 mL / min; Gradient (B%): isocratic 20; Wave Length:254 / 220nm; Rt-1 (min): 10.17; Rt-2 (min): 15.79; sample solvent: EtOH; injection volume: 1.2 mL} to afford (5)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine (peak-1, 38.5 mg, 38% yield) as a yellow solid and (R)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (peak-2, 38.7 mg, 39% yield) as a yellow solid.
[0112] (5)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3 ]heptan- 1 -yl)-[ 1,2,4]triazolo[4,3 -a]pyridin-3 -amine LC-MS: m / z 320.2 [M+H]+. 'HNMR (400 MHz, DMSO-tL) d 8.71-8.69 (m, 1H), 8.16 (d, J= 7.2 Hz, 1H), 7.90 (td, Ji = 1.6 Hz, J2= 7.6 Hz, 1H), 7.72 (d, J= 8.0 Hz, 1H), 7.44-7.40 (m, 1H), 6.76 (d, J= 7.2 Hz, 1H), 6.71 (d, J= 8.0 Hz, 1H), 4.07 (q, J= 8.0 Hz, 1H), 2.30-2.16 (m, 3H), 2.20 (s, 3H), 1.86-1.50 (m, 7H). Chiral HPLC: [column:CHIRALPAK IM-3 4.6*50mm, 3um; solvent: hexane: (EtOH: CH2Cl2= 1:1) (0.1% FA & 0.1% DEA) = 70:30, flow rate: 1 mL / min; injection volume: 1 mL, run time: 4 min]; Rt: 1.64.Attorney Docket No. 059976-517001 WO
[0113] (7?)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)-[l,2,4]triazolo[4,3-a]pyridin-3 -amine LC-MS: m / z 320.2 [M+H]+. 'H NMR (400 MHz, DMSO-rL) d 8.71 (d, J= 4.8 Hz, 1H), 8.16 (d, J= 7.2 Hz, 1H), 7.91 (td, Ji = 1.2 Hz, J2= 7.6 Hz, 1H), 7.73 (d, J= 8.0 Hz, 1H), 7.44-7.41 (m, 1H), 6.76 (d, J= 7.2 Hz, 1H), 6.71 (d, J= 8.0 Hz, 1H), 4.07 (q, J = 8.0 Hz, 1H), 2.30-2.16 (m, 3H), 2.20 (s, 3H), 1.90-1.50 (m, 7H). Chiral HPLC: [column: CHIRALPAK IM-3 4.6*50mm, 3um; solvent: hexane: (EtOH: CH2Cl2= 1:1) (0.1% FA& 0.1% DEA) = 70:30, flow rate: 1 mL / min; injection volume: 1 mL, run time: 4 min]; Rt: 2.31.
[0114] The below compounds were synthesised following a similar procedure to that of examples A-l and A-2 using the indicated reactants, (note: absolute configuration was arbitrarily assigned for all chiral compounds).Attorney Docket No. 059976-517001 WOAttorney Docket No. 059976-517001 WOAttorney Docket No. 059976-517001 WOAttorney Docket No. 059976-517001 WOExample A-16: 7V-cyclobutyl-7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-fl]pyi'idin-3-amineAttorney Docket No. 059976-517001 WOStep-A: 8-bromo-7-methyl-[l,2,4]triazolo[4,3-a]pyridin-3-amine
[0115] To a stirred solution of (3-bromo-4-methyl-2-pyridyl)hydrazine (1 g, 4.95 mmol) in THF (8 mL) was added di(imidazol-l-yl)methanimine (1.60 g, 9.90 mmol) at room temperature and the reaction mixture was stirred at 65 °C for 4 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature, the solid thus obtained was filtered, washed with THF (3 mL) and dried to afford 8-bromo-7-methyl- [l,2,4]triazolo[4,3-a]pyridin-3-amine (860 mg, 72% yield) as a white solid. LCMS: m / z 227.0 [(M+H)+] / 229.0.Step-B: 7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine
[0116] Argon gas was purged through a stirred solution of 8-bromo-7-methyl- [l,2,4]triazolo[4,3-a]pyridin-3-amine (600 mg, 2.64 mmol) and tributyl(2-pyridyl)stannane (1.95 g, 5.28 mmol) in DMF (8 mL) for 10 min before addition of Pd(*Bu3P)2 (271 mg, 0.53 mmol). The reaction mixture was stirred at 110 °C for 6 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-50% MeOH in CH2Q2) to afford 7-methyl-8-(pyridin-2-yl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine (300 mg, 50% yield) as a yellow solid. LCMS: m / z 226.0 [(M+H)+],Step-C: N-(7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-yl)cyclobutanimine
[0117] To a stirred solution of 7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (100 mg, 0.44 mmol) and cyclobutanone (62 mg, 0.89 mmol) in toluene (6 mL) was added titanium ethoxide (1.01 g, 4.44 mmol), and the reaction mixture was stirred at 110 °C for 2 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature and volatiles were removed under reduced pressure to afford N-(7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-yl)cyclobutanimine (100 mg, crude) as a yellow solid, which was carried forward to the next step without any purification. LCMS: m / z T& / 1 [(M+H)+],Attorney Docket No. 059976-517001 WOStep-D: N-cyclobutyl-7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine
[0118] To a stirred solution of N-(7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-yl)cyclobutanimine (crude, 100 mg, assumed 0.36 mmol) in EtOH (20 mL) was added NaBH₃CN (227 mg, 3.61 mmol) and the reaction mixture was stirred at room temperature for 2 h, while monitoring reaction progress by LCMS. After completion, it was quenched over an aqueous saturated solution of NaHCCh (15 mL) and extracted using CH2CI2 (20 mL x 3). The combined organic extracts were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-30% MeOH in CH2Q2) followed by preparative HPLC (ACN / water / 0.1%FA) to afford N-cyclobutyl-7-methyl-8-(pyridin-2-yl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (13.9 mg, 13% yield) as a yellow solid. LCMS: m / z 280.2 [(M+H)+], 'HNMR (400 MHz, DMSO-6): d 8.70 (d, J= 4.8 Hz, 1H), 8.03 (d, J= 7.2 Hz, 1H), 7.92 (t, J= 7.8 Hz, 1H), 7.71 (d, J= 7.8 Hz, 1H), 7.44-7.40 (m, 1H), 6.83 (d, J= 7.8 Hz, 1H), 6.75 (d, J= 7.2 Hz, 1H), 4.28-4.18 (m, 1H), 2.44-2.32 (m, 2H), 2.19 (s, 3H), 2.05-1.99 (m, 2H), 1.78-1.66 (m, 2H).
[0119] The below compounds were synthesized following a similar procedure to that of example A-16 using the indicated reactants.Attorney Docket No. 059976-517001 WOExample A-19 & A-20: (5)-8-(pyridin-2-yl)-7V-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-«]pyi'idin-3-amine & (l?)-8-(pyridin-2-yl)-7V-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-«]pyi'idin-3-amine(absolute stereochemistry is arbitrarily assignedStep-A: [3-bromo-4-(trifluoromethyl)-2-pyridyl]hydrazine
[0120] To a stirred solution of 3-bromo-2-chloro-4-(trifluoromethyl)pyridine (200 mg, 0.76 mmol) in 1,4-dioxane (5 mL) was added hydrazine hydrate (0.7 mL, 11.52 mmol, 85% in water) and the mixture was stirred at 100 °C for 16 h. It was then cooled to room temperature and poured into water (20 mL). Extraction was carried out using EtOAc (30 mL x 3), the combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford [3-bromo-4-(trifluoromethyl)-2-pyridyl]hydrazine (200 mg, crude) as a yellow solid. LCMS: m / z 256.1 [(M+H)+] / 258.Step-B: l-[[3-bromo-4-(trifluoromethyl)-2-pyridyl]amino]-3-spiro[3.3]heptan-3-yl-urea
[0121] To a stirred solution of spiro[3.3]heptan-3-amine;hydrochloride (115 mg, 0.78 mmol) and TEA (632 mg, 6.25 mmol) in anhydrous CH2CI2 (10 mL) was added bis(trichloromethyl)carbonate (232 mg, 0.78 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 1 h. To this was then added [3-bromo-4-(trifluoromethyl)-2-pyridyl]hydrazine (200 mg, 0.78 mmol) at 0 °C and the reaction mixture was allowed to warm to room temperature over 1 h, while monitoring reaction progress by LCMS. After completion, it was poured into water (20 mL) and extraction was carried out using CH2CI2 (20 mL x 3). The combined organic extracts were washed with brine (20 mL), dried overAttorney Docket No. 059976-517001 WOanhydrous Na2SC>4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-50% EtOAc in petroleum ether) to afford l-[[3-bromo-4-(trifluoromethyl)-2-pyridyl]amino]-3-spiro[3.3]heptan-3-yl-urea (250 mg, 81% yield) as a yellow solid. LCMS: 393.1 m / z [(M+H)+] / 395.Step-C: 8-bromo-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3 -amine
[0122] A solution of l-[[3-bromo-4-(trifluoromethyl)-2-pyridyl]amino]-3-spiro[3.3]heptan-3-yl-urea (230 mg, 0.58 mmol) in POCI3 (4 mL, 41 mmol) was stirred at 80 °C for 16 h, before it was cooled to room temperature. It was then poured into ice-water (30 mL) and then basified (pH = 8) using aqueous NaOH (IM). Extraction was carried out using EtOAc (20 mL x 3); the combined organic extracts were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-40% EtOAc in petroleum ether) to afford 8-bromo-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine (202 mg, 92% yield) as a yellow solid. LCMS: 374.7 m / z [(M+H)+] / 376.Step-D: 8-(2-pyridyl)-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyri din-3 -amine
[0123] 8-(2-Pyridyl)-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyri din-3 -amine (yellow solid, 50 mg, 55% yield) was synthesized as described in step-B for the synthesis of example A-16 using 8-bromo-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (90 mg, 0.24 mmol) and tributyl(2-pyridyl)stannane (176 mg, 0.48 mmol) as the starting materials. LCMS: 374.1 m / z [(M+H)+],Step-E: (5)-8-(pyridin-2-yl)-A-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine & (5)-8-(pyridin-2-yl)-A-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine
[0124] A racemic mixture of 8-(2-pyridyl)-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine (50 mg, 0.13 mmol) was resolved by SFC {[(Column: Daicel AD-3 (25*250mm,10um), mobile phase: CO2 / MeOH[0.2% NH3 (7M in MeOH)]=75 / 25 flow rate: 120 ml / min)]} to afford (5)-8-(pyridin-2-yl)-A-(spiro[3.3]heptan-Attorney Docket No. 059976-517001 WOl-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (peak-1, 19.40 mg, 39% yield) as a yellow solid and (7?)-8-(pyridin-2-yl)-7V-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (peak-2, 19.16 mg, 38% yield) as a yellow solid.
[0125] (5)-8-(pyridin-2-yl)-7V-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine. LCMS: 374.1 m / z [(M+H)+], 'HNMR (400 MHz, DMSO-6): δ 8.69 (d, J= 4.6 Hz, 1H), 8.45 (d, J= 7.4 Hz, 1H), 7.95 (td, Ji = 1.6 Hz, J2= 7.6 Hz, 1H), 7.64 (d, J= 7.8 Hz, 1H), 7.53-7.48 (m, 1H), 7.16-7.10 (m, 2H), 4.14 (q, J= 8.0 Hz, 1H), 2.28-2.18 (m, 3H), 1.88-1.50 (m, 7H). Chiral HPLC: [column: AD-34.6*100mm, 3um; solvent: MeOH {0.2% NH3 (7M in MeOH)}, flow rate: 3 mL / min; injection volume: 10 mL, runtime: 6 min]; Rt: 1.61.
[0126] (7?)-8-(pyridin-2-yl)-7V-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine. LCMS: 374.1 m / z [(M+H)+], 'HNMR (400 MHz, DMSO-6): δ 8.69 (d, J= 4.6 Hz, 1H), 8.45 (d, J= 7.4 Hz, 1H), 7.95 (td, Ji = 1.6 Hz, J2= 7.6 Hz, 1H), 7.64 (d, J= 7.8 Hz, 1H), 7.53-7.49 (m, 1H), 7.15-7.11 (m, 2H), 4.13 (q, J= 8.0 Hz, 1H), 2.28-2.18 (m, 3H), 1.86-1.50 (m, 7H). Chiral HPLC: [column: AD-34.6*100mm, 3um; solvent: MeOH {0.2% NH3 (7M in MeOH)}, flow rate: 3 mL / min; injection volume: 10 mL, run time: 6 min]; Rt: 3.32.Example A-21 & A-22: (. S)-8-(l-inethyl-l / / -L2.4-tiiazol-3-yl)-\-(spiio|3.3|heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-fl]pyi'idin-3-amine & ( / ?)-8-(l-methyl-l / / -1.2.4-triazol-3-yl)-7V-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-«]pyi'idin-3-amine (absolute stereochemistry is arbitrarily assigned to both the enantiomers)Step-A: 8-(l-methyl-l,2,4-triazol-3-yl)-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine
[0127] 8-(l-Methyl-l,2,4-triazol-3-yl)-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)- [l,2,4]triazolo[4,3-a]pyridin-3-amine (yellow solid, 61 mg, 60% yield) was synthesized as described in step-B for the synthesis of example A-16 using 8-bromo-N-spiro[3.3]heptan-3-Attorney Docket No. 059976-517001 WOyl-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (100 mg, 0.26 mmol) and tributyl-(l-methyl-l,2,4-triazol-3-yl)stannane (148 mg, 0.39 mmol) as the starting materials. LCMS: 377.9 m / z [(M+H)+],Step-B: (S)-8-( 1 -methyl- \H- 1,2,4-triazol-3 -yl)-7V-(spiro[3.3 ]heptan- 1 -yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine & (A)-8-(l-methyl-l / 7-l,2,4-triazol-3-yl)-A-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine
[0128] A racemic mixture of 8-(l-methyl-l,2,4-triazol-3-yl)-N-spiro[3.3]heptan-3-yl-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (61 mg, 0.16 mmol) was resolved by SFC {(Column: Daicel OZ-3 (25*250mm,10um), mobile phase: CO2 / MeOH[0.2% NH3 (7M in MeOH)]=75 / 25, Flow rate: 100 mL / min)} to afford (5)-8-(l-methyl-l / 7-l,2,4-triazol-3-yl)-A-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (peak-1, 15 mg, 24% yield) as a yellow solid and (A)-8-(l-methyl-l / 7-l,2,4-triazol-3-yl)-A-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine (peak-2, 14.9 mg, 24% yield) as a yellow solid.
[0129] (5)-8-(l-methyl-l / 7-l,2,4-triazol-3-yl)-7V-(spiro[3.3]heptan-l-yl)-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine. LCMS: 378.1 m / z [(M+H)+], 'H NMR (400 MHz, DMSO-6): δ 8.66 (s, 1H), 8.49 (d, J= 7.4 Hz, 1H), 7.15-7.10 (m, 2H), 4.14 (q, J= 7.8 Hz, 1H), 3.97 (s, 3H), 2.28-2.18 (m, 3H), 1.86-1.50 (m, 7H). Chiral HPLC:[column: OZ-34.6* 100mm, 3um; solvent: MeOH {0.2% NH3 (7M in MeOH)}, flow rate: 3 mL / min; injection volume: 10 mL, run time: 4 min]; Rt: 1.26.
[0130] (A)-8-( 1 -methyl- 1H- 1,2,4-triazol-3 -yl)-A-(spiro[3.3 ]heptan- 1 -y 1 )-7-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-3-amine. LCMS: 378.1 m / z [(M+H)+], 'H NMR (400 MHz, DMSO-6): δ 8.66 (s, 1H), 8.49 (d, J= 7.4 Hz, 1H), 7.15-7.10 (m, 2H), 4.14 (q, J= 7.8 Hz, 1H), 3.97 (s, 3H), 2.32-2.18 (m, 3H), 1.90-1.50 (m, 7H). Chiral HPLC:[column: OZ-34.6* 100mm, 3um; solvent: MeOH {0.2% NH3 (7M in MeOH)}, flow rate: 3 mL / min; injection volume: 10 mL, run time: 4 min]; Rt: 1.96.Example C-l & C-2: (5)-7-methyl-8-(pyridin-2-yl)-7V-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine & (7?)-7-methyl-8-(pyridin-2-yl)-7V-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine (absolute stereochemistry was arbitrarily assigned to both the enantiomers)Attorney Docket No. 059976-517001 WOStep-A: 2-chloro-4-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine
[0131] Argon gas was purged through a solution of 3-bromo-2-chloro-4-methyl-pyridine (5 g, 24.22 mmol), KO Ac (7.13 g, 72.65 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (6.15 g, 24.22 mmol) in 1,4-dioxane (10 mL) for 10 min before addition of Pd(dppf)C12 (1.77 g, 2.42 mmol). The reaction mixture was stirred at 100 °C for 12 h before it was cooled to room temperature and poured into water (30 mL). Extraction was carried out using CH2Q2 (50 mL x 3); the combined organic extracts were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-30% MeOH in CH2Q2) to afford 2-chloro-4-methyl-3-(4, 4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (1.6 g, 25% yield) as a white solid. LCMS: m / z 254.0 [(M+H)+] / 256.Step-B: 2'-chloro-4'-methyl-2,3'-bipyridine
[0132] Argon gas was purged through a solution of 2-iodopyridine (2.2 g, 10.73 mmol), 2-chloro-4-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (2.72 g, 10.73 mmol) and K2CO3 (4.45 g, 32.20 mmol) in 1,4-dioxane (8 mL) and water (1.6 mL) for 10 min before addition of Pd(dppf)C12 (1.57 g, 2.15 mmol). The reaction mixture was stirred at 100 °C for 1 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature and poured into water (30 mL). Extraction was carried out using CH2Q2 (50 mL x 3); the combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-30% MeOH inAttorney Docket No. 059976-517001 WOCH2CI2) to afford 2'-chloro-4'-methyl-2,3'-bipyridine (543.13 mg, 22% yield) as a yellow solid. LCMS: m / z 205.2 [(M+H)+] / 207.Step-C: 4'-methyl-[2,3'-bipyridine]-2'-carbonitrile
[0133] Argon gas was purged through a stirred suspension of 2-chloro-4-methyl-3-(2-pyridyl)pyridine (790 mg, 3.86 mmol), Zn (432 mg, 7.72 mmol), Zn(CN)2 (4.53 g, 38.60 mmol) and dppf (642 mg, 1.16 mmol) in DMF (5 mL) for 10 min before addition of Pd2(dba)3 (707 mg, 0.77 mmol). The reaction mixture was stirred at 110 °C for 5 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature and poured into water (30 mL). Extraction was carried out using EtOAc (30 mL x 3); the combined organic extracts were washed with brine (50 mL x 3), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-30% MeOH in CH2Q2) to afford 4'-methyl-[2,3'-bipyridine]-2'-carbonitrile (550 mg, 69% yield) as a yellow solid. LCMS: m / z 196.2 [(M+H)+],Step-D: (4'-methyl-[2,3'-bipyridin]-2'-yl)methanamine
[0134] To a solution of 4-methyl-3-(2-pyridyl)pyridine-2-carbonitrile (230 mg, 1.18 mmol) in anhydrous THF (5 mL) was added LiAlH4 (1 M solution in THF, 1.77 mL) and the reaction mixture was stirred at 0 °C for 1 h, while monitoring reaction progress by LCMS. After completion, it was quenched with addition of ice water (10 mL) and extraction was carried out using EtOAc (30 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (4'-methyl-[2,3'-bipyridin]-2'-yl)methanamine (230 mg, crude) as a yellow solid. LCMS: m / z 200.1 [(M+H)+],Step-E: 1-((4'-methyl-[2,3'-bipyridin]-2'-yl)methyl)-3-(spiro[3.3]heptan-1-yl)urea
[0135] To a solution of spiro[3.3]heptan-3-amine (222 mg, 1.51 mmol, HC1 salt) and TEA (610 mg, 6.02 mmol) in CH2CI2 (10 mL) was added bis(tri chloromethyl) carbonate (224 mg, 0.75 mmol) at 0 °C and the reaction mixture was allowed to warm to room temperature over 1 h. To this was then added [4-methyl-3-(2-pyridyl)-2-pyridyl]methanamine (450 mg, 2.26 mmol) at 0 °C and the reaction mixture was stirred for additional 1 h at room temperature. It was then poured into water (30 mL) and extracted with CH2CI2 (30 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SC>4, filtered andAttorney Docket No. 059976-517001 WOconcentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-30% MeOH in CH2CI2) to afford 1-((4'-methyl-[2,3'-bipyridin]-2'-yl)methyl)-3-(spiro[3.3]heptan-1-yl)urea (220 mg, 75% yield) as a yellow solid. LCMS: m / z 337.2 [(M+H)+],Step-F: (5)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine & (A)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine
[0136] To a stirred solution of l-[[4-methyl-3-(2-pyridyl)-2-pyridyl]methyl]-3-spiro[3.3]heptan-3-yl-urea (220 mg, 0.65 mmol) in toluene (5 mL) was added POCI3 (150 mg, 0.98 mmol, 0.09 mL) and the reaction mixture was stirred at 50 °C for 1 h, while monitoring reaction progress by LCMS. After completion, it was cooled to room temperature and poured into water (10 mL). Extraction was carried out using CH2CI2 (30 mL x 3); the combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (using gradient elution of 0-30% MeOH in CH2Q2) to afford 135 mg of racemic mixture of 7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyri din-3 -amine, which was resolved by SFC {Column: Daicel OS-3 (25*250mm,10um) Mobile phase: CO2 / MeOH [0.2% NH3 (7M in MeOH)]=85 / 15} to afford (S)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine (peak-1, 17.4 mg, 16% yield) as a yellow solid and (A)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine (peak-2, 5 mg, 5% yield) as a yellow solid.
[0137] (5)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine. LCMS: m / z, 319.2 [(M+H)+], 1H NMR (400 MHz, DMSO-d6): δ 8.71-8.69 (m, 1H), 7.93-7.89 (m, 2H), 7.54 (d, J= 7.8 Hz, 1H), 7.43-7.39 (m, 1H), 6.41 (s, 1H), 6.37 (d, J= 8.0 Hz, 1H), 6.25 (d, J= 8.2 Hz, 1H), 4.08 (q, J= 8.2 Hz, 1H), 2.30-2.14 (m, 3H), 2.03 (s, 3H), 1.82-1.50 (m, 7H). Chiral HPLC: [column: OD-3 4.6* 100mm, 3um; solvent: MeOH {0.2% NH3 (7M in MeOH)}, flow rate: 3 mL / min; injection volume: 10 mL, run time: 5 min]; Rt: 1.99.
[0138] (A)-7-methyl-8-(pyridin-2-yl)-N-(spiro[3.3]heptan-l-yl)imidazo[l,5-a]pyridin-3-amine. LCMS: m / z, 319.2 [(M+H)+], 1H NMR (400 MHz, DMSO-d6): δ 8.71-8.69 (m, 1H), 7.93-7.89 (m, 2H), 7.54 (d, J= 7.8 Hz, 1H), 7.43-7.39 (m, 1H), 6.41 (s, 1H), 6.37 (d, J= 7.4 Hz, 1H), 6.25 (d, J= 8.4 Hz, 1H), 4.08 (q, J= 8.2 Hz, 1H), 2.26-2.10 (m, 3H), 2.03 (s, 3H),Attorney Docket No. 059976-517001 WO1.84-1.50 (m, 7H). Chiral HPLC: [column: OD-3 4.6* 100mm, 3um; solvent: MeOH {0.2% NH3 (7M in MeOH)}, flow rate: 3 mL / min; injection volume: 10 mL, run time: 5 min]; Rt: 2.93.
[0139] The below compounds were synthesized following similar procedures to those of the above examples using the appropriate reactants.Biological ExamplesProtein Purification
[0140] The SARMl(50-724)-TEV-ProteinA(32-327) construct was expressed in Expi293 cells. The protein was purified using ion exchange chromatography, and protein A was cleaved using His-TEV followed by IMAC. The protein was then run on size exclusion chromatography with concentrated protein onto a 24mL column. Protein was eluted with 50 mM HEPES, 150 mM NaCl, 10% glycerol, 1 mM TCEP, pH 8.0.NAD-Glo Biochemical Assay
[0141] All reagents were prepared in assay buffer containing 25 mM HEPES pH7.4, 10 mM KC1, 10 mM MgC12, 0.1% BSA. 200 nL of compound or DMSO was added to the 384-well plate (Perkinelmer, #6007290) using Echo dispensing. Then 10 pL of 160 nM SARM1 protein was added to the 384-well plate and incubated for 5 minutes at 25 °C. Then 5 pL of 200 nM NMN (Sigma Aldrich, #N3501) working solution was added to the 384-well plate. After a 20 minute incubation, 5 pL of 120 nM NAD (Sigma Aldrich, #N1636) working solution was added to the 384-well plate and the plate was incubated for 45 min at 25 °C. TheAttorney Docket No. 059976-517001 WOfinal concentrations of SARM1, NMN, and NAD are 80 nM, 50 pM, and 30 pM, respectively.
[0142] After 45min, 20 pL of 0.8% formic acid was added to quench the reaction. The quenched reaction was then diluted 40x using assay buffer, mixed, and transferred to a new 384-well plate. Then 10 pL of NAD / NAD-Glo detection reagent (Promega, #G9027) was added to each well, mixed and incubated at room temperature for 30 minutes. Luminescence was measured on the Envision (Perkin Elmer) and data was analyzed using GraphPad prism. hSARMl HEK293 CTG Assay
[0143] A stable cell line containing the human SARM1 gene, excluding the MTS domain (amino acids 28-724), was cloned into a HEK293 cell background. These “hSARMl HEK293” cells were cultured in high glucose DMEM (Gibco, #11965092) containing 10% FBS (Gibco, #10091-148), 0.5mg / mL G418 (Thermofisher, # 10131031) and 1% P / S at 37°C, 5% CO2 in a cell culture incubator.
[0144] On the first day of the assay, hSARMl HEK293 cells were seeded into a 384 well plate (Greiner, #781080) at a density of 1,500 cells / 35 pL / well. The following day, cells were incubated with 40 nL compound for one hour before 5 pL / well CZ-48 was added to a final concentration of 300pM and incubated overnight at 37°C. The next day, plates were removed from the incubator and allowed to equilibrate to room temperature for around 10 minutes. Cell Titer-Gio (CTG) working solution was prepared according to instructions (Promega, #G7572) and allowed to equilibrate to 25°C. Then 20 pL of CTG reagent was added into each well and centrifuge with 1,000 rpm for 30 s and incubated at RT for 15 min with shaking. The plates were read on an Envision (Perkin Elmer) plate reader and data were analyzed using GraphPad prism.
[0145] The results of the NAD-Glo Biochemical Assay and hSARMl HEK293 CTG Assay are presented in Table 3 below.Table 3. NAD-Glo Biochemical Assay and Inducible SAM-TIR Viability AssayAttorney Docket No. 059976-517001 WO
[0146] Although the foregoing disclosure has been described in some detail by way of illustration and Example for purposes of clarity of understanding, one of skill in the art will appreciate that certain changes and modifications may be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference. Where a conflict exists between the instant disclosure and a reference provided herein, the instant disclosure shall dominate.
Claims
Attorney Docket No. 059976-517001 WOWHAT IS CLAIMED IS:
1. A compound of Formula (I):or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:X is N or CR’;R’ is hydrogen, halo, or C1-3 alkyl;L is absent or C1-2 alkylene;R1is C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl, or 3-10 membered heterocyclyl;R2is C6-12 aryl or 5-10 membered heteroaryl;R3is H, halo, -NR4R5, -CN, -OH, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C3-8 cycloalkyl;andR4and R5are each independently H or C1-3 alkyl,wherein each C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C6-12 aryl, 5-10 membered heteroaryl, C3- 8 cycloalkyl, and 3-10 membered heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, -OH, -NR6R7, C1-3 alkyl, and C1-3 alkoxy, wherein each C1-3 alkyl is optionally further substituted with - OH, and each R6and R7is independently H or C1-3 alkyl.
2. The compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is N.
3. The compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is absent.
4. The compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1is C3-8 cycloalkyl.Attorney Docket No. 059976-517001 WO5. The compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptablesalt of any of the foregoing, wherein R1is -CF3,6. The compound of claim 5, or a stereoisomer thereof, or a pharmaceutically acceptablesalt of any of the foregoing, wherein R1is7. The compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R2is pyridyl.
8. The compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R3is -NR4R5, C1-6 alkyl, or C1-6 haloalkyl.
9. The compound of claim 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R3is -NH2, -CH3, or CF3.
10. The compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is selected from Table 1.
11. A pharmaceutical composition comprising a compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and at least one pharmaceutically acceptable excipient.
12. A method for treating or preventing axonal degeneration in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.Attorney Docket No. 059976-517001 WO13. A method for treating or preventing a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
